Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab Plus Apatinib and Etoposide for HER2-Negative Breast Cancer Brain Metastasis
NCT06418594Phase 2Recruiting
- Sponsor
- The Fifth Medical Center of the PLA General Hospital
- Start
- Oct 2024
- Primary completion
- Nov 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in breast cancer and brain metastases, sponsored by The Fifth Medical Center of the PLA General Hospital. Primary endpoint: Central Nervous System Objective Response Rate at 2 months. Started Oct 2024; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
breast cancerbrain metastases
Beyond the preview
Go deeper on NCT06418594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06418594.